Looking for leads, investment insights, or competitive intelligence?
News about Regeneron Pharmaceuticals
Scientists are ready to move an experimental treatment into phase 1 trials.
“We should only be working on two things, health and the freaking environment.”
But Dupixent's high cost could be a problem.
They say a robust review process is needed to convince doctors and insurers new drugs have value.
It's to protect the company's best-selling drug.